SCHEMBL17050451

SCHEMBL17050451

Oc1ccc(Oc2ccc(Br)cn2)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
GRM8 O00222 1/20 0.40
GRM7 Q14831 1/20 0.40
GRM4 Q14833 1/20 0.40
LMNA P02545 5/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39
NR1I2 O75469 1/20 0.39
TTR P02766 1/20 0.39
PGR P06401 1/20 0.39
HSP90AA1 P07900 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
HSPA5 P11021 1/20 0.39
CBR1 P16152 1/20 0.39
TBXA2R P21731 1/20 0.39
SLC6A2 P23975 1/20 0.39
AGTR1 P30556 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KMT2A Q03164 3/20 0.38
POLB P06746 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17050816 0.83 L3MBTL1 (0.42) L3MBTL1GRM8GRM7GRM4LMNA
SCHEMBL17050467 0.82 KDM4E (0.43) L3MBTL1GRM8GRM7GRM4LMNA
SCHEMBL17050452 0.79 MAPK8 (0.43) L3MBTL1HPGDSLC6A2SLC6A3KMT2A
SCHEMBL17050461 0.79 SLC6A4 (0.41) L3MBTL1HPGDACACBKDM4E
SCHEMBL17050839 0.78 TTR (0.48) L3MBTL1GRM8GRM7GRM4LMNA
SCHEMBL28714581 0.78 KMT2A (0.60) L3MBTL1GRM8GRM7GRM4LMNA
SCHEMBL30700673 0.78 KMT2A (0.60) L3MBTL1GRM8GRM7GRM4LMNA
SCHEMBL29479486 0.78 KMT2A (0.60) L3MBTL1GRM8GRM7GRM4LMNA
SCHEMBL17050453 0.77 ACACB (0.53) L3MBTL1MAPTHPGDKMT2APOLB
SCHEMBL17050471 0.76 ACACB (0.55) SMN1; SMN2TSHRACACBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE SHIONOGI & CO., LTD. (JP) 2015-09-03 US disclosed
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE SHIONOGI & CO., LTD. (JP) 2015-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE ACSS2, ACACB, ACAT2 L3MBTL1 3849/4885GRM8 3061/4885GRM7 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.